Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2018
Phase 1b. To evaluate the safety and tolerability of subcutaneous (SC) dose administrations of Efavaleukin alfa in subjects with active rheumatoid arthritis (RA). Phase 2a. To evaluate the efficacy of Efavaleukin alfa at week 12 as measured by the American College of Rheumatology 20 percent improvement criteria (ACR 20) in adult subjects with moderate to severe RA.
Epistemonikos ID: 61de97671cd754b7060a82c0ef16f3833858748a
First added on: Mar 23, 2022